Anticoagulation in Atrial Fibrillation

References

1. [1]

   McBride D, Brüggenjürgen B, Roll S et al.. “Anticoagulation treatment for the reduction of stroke in atrial fibrillation: a cohort study to examine the gap between guidelines and routine medical practice.” Journal of thrombosis and thrombolysis (2007). PMID: 17260164 ↗

   L2bCOHORTCited in: Epidemiology and Stroke Risk
2. [2]

   Wyss R, Ellis AR, Brookhart MA et al.. “Matching on the disease risk score in comparative effectiveness research of new treatments.” Pharmacoepidemiology and drug safety (2015). PMID: 26112690 ↗

   L5OTHERCited in: Epidemiology and Stroke Risk
3. [3]

   Go AS, Reed GL, Hylek EM et al.. “Factor V Leiden and risk of ischemic stroke in nonvalvular atrial fibrillation: the AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study.” Journal of thrombosis and thrombolysis (2003). PMID: 14574075 ↗

   L5OTHERCited in: Epidemiology and Stroke Risk
4. [4]

   Dallongeville J, Sacher F, Bouée S et al.. “Xafran, a drug utilization study of rivaroxaban in stroke prevention in atrial fibrillation in France using a claim database.” Therapie (2018). PMID: 30075870 ↗

   L5OTHERCited in: Epidemiology and Stroke Risk
5. [5]

   Ariyanti D, Hibatulloh MF, Pramusinta CK et al.. “The Role of CHA₂DS₂-VASc Score in Predicting Clinical Complications Following Primary Percutaneous Coronary Intervention: A Systematic Review and Meta-Analysis.” Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions (2025). PMID: 41047624 ↗

   L2aSR_OBSCited in: Ischemic Risk Stratification
6. [6]

   Dorsch MP, Flynn AJ, Greer KM et al.. “A Web-Based Tool to Perform a Values Clarification for Stroke Prevention in Patients With Atrial Fibrillation: Design and Preliminary Testing Study.” JMIR cardio (2025). PMID: 40215398 ↗

   L1bRCTCited in: Ischemic Risk Stratification
7. [7]

   Hammad A, Ahmad A, Khalid N et al.. “Efficacy and safety of left atrial appendage occlusion for atrial fibrillation in patients with a history of prior intracranial hemorrhage: a systematic review and meta-analysis of observational studies.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2026). PMID: 41026441 ↗

   L2aSR_OBSCited in: Ischemic Risk Stratification, Bleeding Risk Assessment
8. [8]

   Tsiartas E, Samaras A, Papazoglou AS et al.. “Changes in CHA2DS2-VASc score and risk of ischemic stroke among patients with atrial fibrillation.” Heart and vessels (2023). PMID: 37311823 ↗

   L1bRCTCited in: Ischemic Risk Stratification
9. [9]

   Mahawish KM, White H, Feigin V et al.. “Refining predictive risk models for stroke in atrial fibrillation: a scoping review and meta-analysis for Aotearoa New Zealand, Māori and Pacific peoples.” The New Zealand medical journal (2025). PMID: 40080765 ↗

   L2aSR_OBSCited in: Ischemic Risk Stratification
10. [10]

    Ali A, Siddiqui AA, Ali M et al.. “Meta-analysis on performance of ABC and GARFIELD-AF compared to CHA2DS2-VASc and HAS-BLED in anticoagulated atrial fibrillation patients.” Cardiovascular revascularization medicine : including molecular interventions (2024). PMID: 37880043 ↗

    L2aSR_OBSCited in: Ischemic Risk Stratification, Bleeding Risk Assessment
11. [11]

    Trinks-Roerdink EM, Geersing GJ, van den Dries CJ et al.. “Integrated care in patients with atrial fibrillation- a predictive heterogeneous treatment effect analysis of the ALL-IN trial.” PloS one (2023). PMID: 37856486 ↗

    L1bRCTCited in: Ischemic Risk Stratification
12. [12]

    Artola Arita V, Van De Lande ME, Khalilian Ekrami N et al.. “Clinical utility of the 4S-AF scheme in predicting progression of atrial fibrillation: data from the RACE V study.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2023). PMID: 36857318 ↗

    L2bTRIAL_NONRANDOMCited in: Ischemic Risk Stratification
13. [13]

    Jalli E, Jaakkola J, Langén V et al.. “Venous thromboembolisms and stroke risk in patients with atrial fibrillation: a nationwide cohort study.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2025). PMID: 40726063 ↗

    L2bCOHORTCited in: Ischemic Risk Stratification
14. [14]

    Boettger P, Sedighi J, Piayda K et al.. “Clinical implications of the recalibrated CHA₂DS₂-VA score for women after ischemic stroke: a prospective cohort study.” Acta neurologica Belgica (2025). PMID: 41082160 ↗

    L2bCOHORTCited in: Ischemic Risk Stratification
15. [15]

    Nicolas J, Dangas G, Borrow A et al.. “Comparative Performance of Machine Learning and Traditional Risk Scores in Predicting Adverse Events After Transcatheter Aortic Valve Replacement in Patients With Atrial Fibrillation.” The American journal of cardiology (2026). PMID: 41407062 ↗

    L1bRCTCited in: Bleeding Risk Assessment
16. [16]

    Gerdisch MW, Garrett HE, Mumtaz MA et al.. “Prophylactic Left Atrial Appendage Exclusion in Cardiac Surgery Patients With Elevated CHA2DS2-VASc Score: Results of the Randomized ATLAS Trial.” Innovations (Philadelphia, Pa.) (2022). PMID: 36373654 ↗

    L1bRCTCited in: Bleeding Risk Assessment
17. [17]

    Deng JL, He L, Jiang C et al.. “[A comparison of CAS risk model and CHA2DS2-VASc risk model in guiding anticoagulation treatment in Chinese patients with non-valvular atrial fibrillation].” Zhonghua xin xue guan bing za zhi (2022). PMID: 36096706 ↗

    L1bRCTCited in: Bleeding Risk Assessment
18. [18]

    Yang W, Hou X, Meng X et al.. “[Control study of the intelligent calculation method and the traditional calculation method in risk assessments of hospitalization].” Zhonghua wei zhong bing ji jiu yi xue (2022). PMID: 35728858 ↗

    L1bRCTCited in: Bleeding Risk Assessment
19. [19]

    Shurrab M, Austin PC, Jackevicius CA et al.. “Apixaban vs rivaroxaban in patients with atrial fibrillation at high or low bleeding risk: A population-based cohort study.” Heart rhythm (2025). PMID: 39154873 ↗

    L2bCOHORTCited in: Bleeding Risk Assessment
20. [20]

    Wang W, Saczynski JS, Lessard D et al.. “Presence of Geriatric Conditions Is Prognostic of Major Bleeding in Older Patients with Atrial Fibrillation: a Cohort Study.” Journal of general internal medicine (2022). PMID: 35102482 ↗

    L2bCOHORTCited in: Bleeding Risk Assessment
21. [21]

    Chao TF, Chan YH, Tuan TC et al.. “Should oral anticoagulants still be prescribed to patients with atrial fibrillation with a single stroke risk factor but at high bleeding risk? A nationwide cohort study.” European heart journal. Quality of care & clinical outcomes (2022). PMID: 34302335 ↗

    L2bCOHORTCited in: Bleeding Risk Assessment
22. [22]

    Kow CS, Chen F, Jie Leong SK et al.. “Bleeding risk assessment tools in patients with atrial fibrillation taking anticoagulants: a comparative review and clinical implications.” Expert review of cardiovascular therapy (2025). PMID: 40550625 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Risk Assessment
23. [23]

    Yu JS, Cho MS, Kang DY et al.. “Impact of Atrial Fibrillation Pattern on Edoxaban Antithrombotic Therapy in Patients With Atrial Fibrillation and Stable Coronary Artery Disease: A Secondary Analysis of the EPIC-CAD Randomized Clinical Trial.” Journal of the American Heart Association (2026). PMID: 41848064 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations
24. [24]

    Kimura K, Nishiyama Y, Iwasaki YK et al.. “Catheter Ablation and Oral Anticoagulation for Secondary Stroke Prevention in Atrial Fibrillation: The STABLED Randomized Clinical Trial.” JAMA neurology (2026). PMID: 41770549 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations, Perioperative and Periprocedural Management
25. [25]

    Fasth O, Oldgren J, Ghukasyan Lakic T et al.. “Early versus delayed DOAC after ischaemic stroke in atrial fibrillation: 1-year outcomes in the TIMING study and in concurrent practice.” European stroke journal (2026). PMID: 41758561 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations
26. [26]

    Al Said S, Patel SM, Giugliano RP et al.. “Abelacimab vs Rivaroxaban in Older Individuals With Atrial Fibrillation: A Prespecified Analysis of the Phase 2b AZALEA-TIMI 71 Trial.” JAMA cardiology (2026). PMID: 41637102 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations
27. [27]

    Polymeris AA, Rossel JB, Koga M et al.. “Once- versus twice-daily direct oral anticoagulants after ischemic stroke in atrial fibrillation - A post-hoc analysis of the ELAN trial.” European stroke journal (2026). PMID: 41614485 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations
28. [28]

    Yamanaka S, Noda T, Nochioka K et al.. “Prognostic impact of systolic blood pressure and antithrombotic strategy in patients with atrial fibrillation and stable coronary artery disease: a post-hoc analysis of the AFIRE trial.” Hypertension research : official journal of the Japanese Society of Hypertension (2026). PMID: 41486379 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs), Management in Special Populations
29. [29]

    Gologorsky R, Lansberg MG, Wintermark M et al.. “Multiterritory Brain Infarcts, Anticoagulation, and Recurrence After Cryptogenic Stroke: A Subgroup Analysis of the ARCADIA Trial.” Stroke (2026). PMID: 41347300 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs)
30. [30]

    Liang M, Jin J, Zhao R et al.. “Dabigatran-based versus warfarin-based triple antithrombotic regimen with a 1-month intensification after coronary stenting in patients with nonvalvular atrial fibrillation (COACH-AF PCI).” BMC medicine (2025). PMID: 41254594 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs)
31. [31]

    Siegal DM, Sticherling C, Healey JS et al.. “Major Bleeding With Apixaban vs Aspirin: A Subanalysis of the ARTESiA Randomized Clinical Trial.” JAMA cardiology (2025). PMID: 41222953 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs)
32. [32]

    Lee SJ, Yu HT, Lee YJ et al.. “Therapy for Atrial Fibrillation in Patients with Drug-Eluting Stents.” The New England journal of medicine (2026). PMID: 41211917 ↗

    L1bRCTCited in: Direct Oral Anticoagulants (DOACs)
33. [33]

    Landmesser U, Skurk C, Kirchhof P et al.. “Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation.” The New England journal of medicine (2026). PMID: 41849741 ↗

    L1bRCTCited in: Management in Special Populations
34. [34]

    Haimovich JS, Kany S, Chang Y et al.. “Incidence, Risk Factors, and Outcomes in Stressor-Associated Atrial Fibrillation: Insights From the VITAL-AF Trial.” Circulation (2026). PMID: 41662456 ↗

    L1bRCTCited in: Management in Special Populations
35. [35]

    Rivard L, Khairy P, Talajic M et al.. “Anticoagulation to prevent ischemic stroke and neurocognitive impairment in atrial fibrillation: the BRAIN-AF randomized clinical trial.” Nature medicine (2026). PMID: 41501492 ↗

    L1bRCTCited in: Management in Special Populations
36. [36]

    Olsen FJ, Diederichsen SZ, Jørgensen PG et al.. “Effects of Atrial Fibrillation Screening According to Echocardiographic Measures of Cardiac Structure and Function: A Post Hoc Analysis of the LOOP Randomized Clinical Trial.” Journal of the American Heart Association (2026). PMID: 41467399 ↗

    L1bRCTCited in: Management in Special Populations
37. [37]

    Younis A, Nair DG, Di Biase L et al.. “Atrial Fibrillation Recurrence After Left Atrial Appendage Occlusion in Patients Undergoing Ablation: The OPTION Trial Sub analysis.” JACC. Clinical electrophysiology (2026). PMID: 41201405 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
38. [38]

    Saliba W, Nair D, Swarup V et al.. “Comparison of left atrial appendage closure and oral anti-coagulation after catheter ablation for atrial fibrillation: Concomitant and sequential cohorts of the OPTION randomized controlled trial.” Heart rhythm (2025). PMID: 40288474 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
39. [39]

    Gruwez H, De Melio N, Vermunicht P et al.. “Improving atrial fibrillation or flutter detection and management by smartphone-based photoplethysmography rhythm monitoring following cardiac surgery: a pragmatic randomized trial.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2025). PMID: 39823508 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
40. [40]

    Ikami Y, Izumi D, Fujiki S et al.. “Differences in coagulation responses to vascular injury between uninterrupted dabigatran and apixaban: A clinical prospective randomized study.” Heart rhythm (2025). PMID: 39019384 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
41. [41]

    Schrickel JW, Beiert T, Linhart M et al.. “Prevention of cerebral thromboembolism by oral anticoagulation with dabigatran after pulmonary vein isolation for atrial fibrillation: the ODIn-AF trial.” Clinical research in cardiology : official journal of the German Cardiac Society (2024). PMID: 37921923 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
42. [42]

    Providencia R, Ali H, Barra S et al.. “Ablation of atrial fibrillation and risk of stroke: A meta-analysis.” Heart rhythm (2026). PMID: 40398548 ↗

    L2aSR_OBSCited in: Perioperative and Periprocedural Management
43. [43]

    Nakano T, Oka T, Okayama K et al.. “Association between oral anticoagulants continuation on thromboembolism and bleeding events in patients with CHADS2 score 0-2 points after catheter ablation for persistent atrial fibrillation.” Journal of cardiology (2025). PMID: 40287088 ↗

    L1bRCTCited in: Perioperative and Periprocedural Management
44. [44]

    Lin AL, Allen K, Gutierrez JA et al.. “Care for Atrial Fibrillation and Outcomes in Rural Versus Urban Communities in the United States: A Systematic and Narrative Review.” Journal of the American Heart Association (2025). PMID: 40028844 ↗

    L2aSR_OBSCited in: Perioperative and Periprocedural Management
45. [45]

    Sawalha K, Alakchar M, Mamas MA et al.. “Safety of cardioversion without anticoagulation in patients' status post left atrial appendage occlusion: A systematic review and meta-analysis.” Cardiovascular revascularization medicine : including molecular interventions (2026). PMID: 40877076 ↗

    L2aSR_OBSCited in: Perioperative and Periprocedural Management
46. [46]

    Connolly SJ, Sharma M, Cohen AT et al.. “Andexanet for Factor Xa Inhibitor-Associated Acute Intracerebral Hemorrhage.” The New England journal of medicine (2024). PMID: 38749032 ↗

    L1bRCTCited in: Bleeding Management and Reversal Agents
47. [47]

    Shahjouei S, Tsivgoulis G, Goyal N et al.. “Safety of Intravenous Thrombolysis Among Patients Taking Direct Oral Anticoagulants: A Systematic Review and Meta-Analysis.” Stroke (2020). PMID: 31884908 ↗

    L2aSR_OBSCited in: Bleeding Management and Reversal Agents
48. [48]

    Katsanos AH, Schellinger PD, Köhrmann M et al.. “Fatal oral anticoagulant-related intracranial hemorrhage: a systematic review and meta-analysis.” European journal of neurology (2018). PMID: 29953696 ↗

    L2aSR_OBSCited in: Bleeding Management and Reversal Agents
49. [49]

    Douketis JD, Spyropoulos AC. “Perioperative Management of Patients Taking Direct Oral Anticoagulants: A Review.” JAMA (2024). PMID: 39133476 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
50. [50]

    Costache RS, Dragomirică AS, Gheorghe BE et al.. “Oral Anticoagulation in Patients with Chronic Liver Disease.” Medicina (Kaunas, Lithuania) (2023). PMID: 36837547 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
51. [51]

    Crawley RM, Anderson RL. “Prevention and Treatment of Bleeding with Direct Oral Anticoagulants.” Drugs (2020). PMID: 32691292 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
52. [52]

    Rali P, Gangemi A, Moores A et al.. “Direct-Acting Oral Anticoagulants in Critically Ill Patients.” Chest (2019). PMID: 31251908 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
53. [53]

    Gerner ST, Huttner HB. “Patients on NOACs in the Emergency Room.” Current neurology and neuroscience reports (2019). PMID: 31144111 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
54. [54]

    Milling TJ, Ziebell CM. “A review of oral anticoagulants, old and new, in major bleeding and the need for urgent surgery.” Trends in cardiovascular medicine (2020). PMID: 30952383 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
55. [55]

    Leitch J, van Vlymen J. “Managing the perioperative patient on direct oral anticoagulants.” Canadian journal of anaesthesia = Journal canadien d'anesthesie (2017). PMID: 28429198 ↗

    L5REVIEW_NARRATIVECited in: Bleeding Management and Reversal Agents
56. [56]

    Gangireddy SR, Halperin JL, Fuster V et al.. “Percutaneous left atrial appendage closure for stroke prevention in patients with atrial fibrillation: an assessment of net clinical benefit.” European heart journal (2012). PMID: 23008509 ↗

    L1bRCTCited in: Non-Pharmacologic Alternatives (LAAO)
57. [57]

    Munkholm-Larsen S, Cao C, Yan TD et al.. “Percutaneous atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review.” Heart (British Cardiac Society) (2012). PMID: 22511532 ↗

    L2aSR_OBSCited in: Non-Pharmacologic Alternatives (LAAO)
58. [58]

    Bode WD, Patel N, Gehi AK. “Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis.” Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing (2015). PMID: 25711953 ↗

    L2aSR_OBSCited in: Non-Pharmacologic Alternatives (LAAO)
59. [59]

    Piccini JP, Sievert H, Patel MR. “Left atrial appendage occlusion: rationale, evidence, devices, and patient selection.” European heart journal (2017). PMID: 27628431 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
60. [60]

    Belgaid DR, Khan Z, Zaidi M et al.. “Prospective randomized evaluation of the watchman left atrial appendage closure device in patients with atrial fibrillation versus long-term warfarin therapy: The PREVAIL trial.” International journal of cardiology (2016). PMID: 27343417 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
61. [61]

    Jin Q, Yang J, Wu S et al.. “Massive hemoptysis after left atrial appendage occlusion in a patient with atrial fibrillation and left atrial appendage thrombus: a case report.” BMC cardiovascular disorders (2026). PMID: 41491151 ↗

    L4CASE_REPORTCited in: Non-Pharmacologic Alternatives (LAAO)
62. [62]

    Alli O, Holmes D. “Left atrial appendage occlusion.” Heart (British Cardiac Society) (2015). PMID: 25518846 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
63. [63]

    Whitlock RP, Hanif H, Danter M. “Nonpharmacologic approaches to stroke prevention in atrial fibrillation.” The Canadian journal of cardiology (2013). PMID: 23790602 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
64. [64]

    Landmesser U, Holmes DR. “Left atrial appendage closure: a percutaneous transcatheter approach for stroke prevention in atrial fibrillation.” European heart journal (2012). PMID: 22041550 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
65. [65]

    Akella K, Yarlagadda B, Murtaza G et al.. “Epicardial versus Endocardial Closure: Is One Better than the Other?” Cardiac electrophysiology clinics (2020). PMID: 32067652 ↗

    L5REVIEW_NARRATIVECited in: Non-Pharmacologic Alternatives (LAAO)
66. [66]

    Shahid S, Iqbal M, Shahabi M et al.. “Factor XIa Inhibitors Versus Direct Oral Anticoagulants for Atrial Fibrillation: A Systematic Review and Meta-analysis of Randomized Controlled Trials.” Cardiovascular drugs and therapy (2026). PMID: 40560486 ↗

    L1aSR_MA_RCTCited in: Current Guidelines and Emerging Therapies
67. [67]

    Campello E, Cappugi C, Catalani F et al.. “Management of Anticoagulant Therapy in Athletes and Sportspeople: Italian Federation of Centers for Diagnosis and Surveillance of the Antithrombotic Therapies (FCSA) Position Paper.” Thrombosis and haemostasis (2025). PMID: 40499916 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
68. [68]

    Carlin S, Cuker A, Gatt A et al.. “Anticoagulation for stroke prevention in atrial fibrillation and treatment of venous thromboembolism and portal vein thrombosis in cirrhosis: guidance from the SSC of the ISTH.” Journal of thrombosis and haemostasis : JTH (2024). PMID: 38823454 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
69. [69]

    Wang Y, Guo Y, Qin M et al.. “2024 Chinese Expert Consensus Guidelines on the Diagnosis and Treatment of Atrial Fibrillation in the Elderly, Endorsed by Geriatric Society of Chinese Medical Association (Cardiovascular Group) and Chinese Society of Geriatric Health Medicine (Cardiovascular Branch): Executive Summary.” Thrombosis and haemostasis (2024). PMID: 38744425 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
70. [70]

    Chao TF, Joung B, Takahashi Y et al.. “2021 Focused Update Consensus Guidelines of the Asia Pacific Heart Rhythm Society on Stroke Prevention in Atrial Fibrillation: Executive Summary.” Thrombosis and haemostasis (2022). PMID: 34773920 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
71. [71]

    Sulzgruber P, Wassmann S, Semb AG et al.. “Oral anticoagulation in patients with non-valvular atrial fibrillation and a CHA2DS2-VASc score of 1: a current opinion of the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy and European Society of Cardiology Council on Stroke.” European heart journal. Cardiovascular pharmacotherapy (2019). PMID: 31119266 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
72. [72]

    Angiolillo DJ, Goodman SG, Bhatt DL et al.. “Antithrombotic Therapy in Patients With Atrial Fibrillation Treated With Oral Anticoagulation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2018 Update.” Circulation (2018). PMID: 30571525 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
73. [73]

    Andrade JG, Verma A, Mitchell LB et al.. “2018 Focused Update of the Canadian Cardiovascular Society Guidelines for the Management of Atrial Fibrillation.” The Canadian journal of cardiology (2018). PMID: 30404743 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
74. [74]

    Steffel J, Verhamme P, Potpara TS et al.. “The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: executive summary.” Europace : European pacing, arrhythmias, and cardiac electrophysiology : journal of the working groups on cardiac pacing, arrhythmias, and cardiac cellular electrophysiology of the European Society of Cardiology (2018). PMID: 29562331 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies
75. [75]

    Angiolillo DJ, Goodman SG, Bhatt DL et al.. “Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention: A North American Perspective-2016 Update.” Circulation. Cardiovascular interventions (2016). PMID: 27803042 ↗

    L1cGUIDELINECited in: Current Guidelines and Emerging Therapies